SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Susan B. Anthony
| Patient | Susan B. Anthony |
|---|
| Date of birth | 1941-02-15 |
|---|
| Identifiers | MRN HR-NI014-SYN; SSN (made up) 000-14-7302 |
|---|
| Document date | 2026-09-28 |
|---|
| Author | Harold Pemberton, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Chief Complaint
Six-month heart failure review. [S]
History of Present Illness
Miss Anthony returns for her six-month review. She is back to lecturing twice a month and travelling by train, and walks two miles most days. She needed as-needed furosemide twice in three months, both after long train days with restaurant meals, and her weight returned to 56 kg within a day each time. Her cough from the August bronchitis has cleared. She has had no dizziness, falls, or breathlessness except on long stair climbs. [S]
| Element | Detail |
|---|
| Interval change | Back to full activity; bronchitis resolved |
| As-needed diuretic | Two doses in three months, after travel days |
| Weight diary | Stable at 56 kg |
| Function | Lecturing twice a month; walking two miles |
| NYHA class | I to II |
Review of Systems
| System | Result | Finding |
|---|
| Constitutional | Negative | Weight stable; good energy |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or edema |
| Respiratory | Negative | Cough resolved; breathless only on long climbs |
| Neurological | Negative | No dizziness on standing |
4 systems reviewed. [S]
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Furosemide 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-16 to 2026-06-29 | completed | S |
| Furosemide 20 mg oral tablet, one tablet by mouth as needed for a weight gain of more than 1 kg in a day or 2 kg in a week | One tablet by mouth once daily as needed for weight gain | Oral route | 2026-06-29 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-16 | active | S |
| Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily | One-half tablet by mouth daily | Oral route | 2026-03-30 | active | S |
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 2026-09-28 | Body height | 165 | cm | S |
| 2026-09-28 | Body weight | 56 | kg | S |
| 2026-09-28 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-09-28 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-09-28 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-09-28 | Heart rate | 70 | /min | S |
| 2026-09-28 | Respiratory rate | 16 | /min | S |
| 2026-09-28 | Body temperature | 36.6 | Cel | S |
| 2026-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-09-28 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 63 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-28 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-28 | Overall summary score [KCCQ-12] | 76 | {score} | | | S |
Physical Exam
Vital signs recorded on 2026-09-28; see the Vital Signs section. [S]
| System | Finding |
|---|
| General | Well |
| Neck | Jugular venous pressure 6 cm |
| Lungs | Clear |
| Heart | Regular rhythm; soft S4 |
| Extremities | No edema |
| Orthostatic blood pressure | No fall on standing |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Heart failure with preserved ejection fraction, NYHA class II to III at diagnosis; synthetic modern diagnosis linked to the documented 1906 heart failure | active | confirmed |
I50.32 | S — Synthetic diagnosis confirmed by echocardiogram in the modern episode; the 1906 cause of death remains D. |
| Hypertensive heart disease with heart failure | active | confirmed |
I11.0 | S — Synthetic diagnosis; no blood pressure from her lifetime is recorded in the cited sources. |
| Acute viral bronchitis after a head cold, resolved without antibiotics | resolved | confirmed |
J20.9 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
Assessment and Plan
- Heart failure with preserved ejection fraction, stable (I50.32). Euvolemic on empagliflozin and spironolactone with rare as-needed furosemide. KCCQ-12 76, up 24 points from baseline. Kidney function and potassium stable (eGFR 63, potassium 4.6). [S]
- Continue the current regimen and the travel weight plan.
- Basic metabolic panel and KCCQ-12 every three to six months on the CMID schedule.
- Hypertensive heart disease (I11.0). Blood pressure 126/72 mmHg, below the 130/80 target without orthostatic symptoms. [S]
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|
| Laboratory | Basic metabolic panel | Every 3 to 6 months when stable | Completed today | Potassium 4.6, eGFR 63 |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit | Completed today | Euvolemic; orthostatic check normal |
| Survey | NYHA functional class | Every visit | Completed today | Class I to II |
| Survey | KCCQ-12 | Every 3 to 6 months | Completed today | 76, up 24 points from baseline |
| Survey | Depression screen (PHQ-2) | Periodically | Due | Planned at next month's annual wellness visit |
| Laboratory | Iron studies, lipid panel, HbA1c, TSH | Annually | Up to date | Drawn at diagnosis in March; due again next spring |
| Imaging | Echocardiogram | Only with unexplained clinical change | Not indicated | Clinically stable |
| Medication safety | Influenza vaccine | Every season | Due | Planned at next month's annual wellness visit |
Goal progress:
- Reach euvolemia with no ankle edema and a stable dry weight within three months. Outcome by 2026-06-29: Dry weight 56 kg; furosemide changed to as-needed use [S]
- Improve the KCCQ-12 overall summary score by at least 15 points by the three-month review. Outcome by 2026-06-29: KCCQ-12 rose from 52 to 70 [S]
- Lower blood pressure below 130/80 by the six-month review without orthostatic symptoms. Outcome by 2026-09-28: Blood pressure 126/72; no dizziness on standing [S]
- Resume a full speaking and travel schedule by the six-month review. Outcome by 2026-09-28: Back to lecturing twice a month with a travel weight plan [S]
Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026)
Follow-up: Annual wellness visit next month. Heart failure review with laboratory tests in three to six months. Next scheduled visit 2026-10-19: subsequent annual wellness visit. [S]